Published in Antimicrob Agents Chemother on January 01, 1991
Aminoglycosides: activity and resistance. Antimicrob Agents Chemother (1999) 3.11
Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrob Agents Chemother (2005) 2.20
Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob Agents Chemother (1997) 2.09
Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2005) 1.78
Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev (2012) 1.74
Aminoglycosides--50 years on. Br J Clin Pharmacol (1995) 1.65
MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother (2003) 1.58
Pharmacodynamics of trovafloxacin, ofloxacin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob Agents Chemother (1999) 1.46
Adaptive resistance following single doses of gentamicin in a dynamic in vitro model. Antimicrob Agents Chemother (1992) 1.24
In vitro characterization of aminoglycoside adaptive resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1996) 1.16
Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother (2011) 1.12
Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model. Antimicrob Agents Chemother (1997) 1.04
Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases. Infection (2016) 0.97
Time-survival studies for quantifying effects of azlocillin and tobramycin on Pseudomonas aeruginosa. Antimicrob Agents Chemother (1994) 0.96
Rationale behind high-dose amoxicillin therapy for acute otitis media due to penicillin-nonsusceptible pneumococci: support from in vitro pharmacodynamic studies. Antimicrob Agents Chemother (1997) 0.95
Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa. Antimicrob Agents Chemother (1998) 0.94
Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants. Antimicrob Agents Chemother (2011) 0.93
Influence of pH on adaptive resistance of Pseudomonas aeruginosa to aminoglycosides and their postantibiotic effects. Antimicrob Agents Chemother (1996) 0.92
Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children. Antimicrob Agents Chemother (1992) 0.92
Pharmacokinetic and pharmacodynamic approach for comparing two therapeutic regimens using amikacin. Antimicrob Agents Chemother (1994) 0.84
Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy. Antimicrob Agents Chemother (2015) 0.80
Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa. J Antimicrob Chemother (2016) 0.78
Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia. Arch Dis Child (1999) 0.77
Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis (1988) 7.50
Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis (1987) 5.63
Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother (1987) 5.17
Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis (1989) 4.79
Involvement of the outer membrane in gentamicin and streptomycin uptake and killing in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1981) 3.95
Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J (1974) 3.42
Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics. J Infect Dis (1986) 2.77
Interaction of polycationic antibiotics with Pseudomonas aeruginosa lipopolysaccharide and lipid A studied by using dansyl-polymyxin. Antimicrob Agents Chemother (1986) 2.74
Roles of ribosomal binding, membrane potential, and electron transport in bacterial uptake of streptomycin and gentamicin. Antimicrob Agents Chemother (1983) 2.58
Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice. J Infect Dis (1983) 2.56
Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med (1984) 2.54
The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis (1984) 2.44
Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis (1983) 2.41
Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model. J Infect Dis (1982) 2.27
Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis (1990) 2.11
Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis (1988) 1.90
Binding of polycationic antibiotics and polyamines to lipopolysaccharides of Pseudomonas aeruginosa. J Bacteriol (1985) 1.90
Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin. J Infect Dis (1971) 1.89
The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis (1979) 1.83
Constant infusions vs. intermittent doses of gentamicin against Pseudomonas aeruginosa in vitro. J Infect Dis (1982) 1.82
Simultaneous antibiotic levels in "breakthrough" gram-negative rod bacteremia. Am J Med (1976) 1.62
Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J Antimicrob Chemother (1978) 1.50
Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis (1989) 1.38
The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis (1988) 1.36
Single-dose daily gentamicin therapy in urinary tract infection. Antimicrob Agents Chemother (1974) 1.12
Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits. J Infect Dis (1977) 1.08
The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis (1990) 1.05
Biphasic, concentration-dependent and rate-limited, concentration-independent bacterial killing by an aminoglycoside antibiotic. J Infect Dis (1984) 0.98
Determinants of the efficacy of tobramycin therapy against isogenic nonmucoid and mucoid derivatives of Pseudomonas aeruginosa PAO1 growing in peritoneal chambers in mice. Antimicrob Agents Chemother (1989) 0.84
Adaptive alterations in the outer membrane of gram-negative bacteria during human infection. Can J Microbiol (1988) 0.83
Intravenous gentamicin therapy for infections in patients with cancer. J Infect Dis (1971) 0.81
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli. J Med Chem (1987) 0.79
Computer-controlled in-vitro simulation of multiple dosing regimens. J Antimicrob Chemother (1985) 0.79
Massive amikacin "overdose". Ann Intern Med (1979) 0.78
Activity of aminoglycoside antibiotics aganst Pseudomonas aeruginosa: specificity and site of calcium and magnesium antagonism. J Infect Dis (1973) 3.67
Pharmacology of gentamicin in man. J Infect Dis (1971) 3.16
Current therapeutics. 234. Gentamicin. Practitioner (1967) 2.54
Laboratory and clinical conditions for gentamicin inactivation by carbenicillin. Arch Intern Med (1972) 2.19
Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis (1990) 2.11
A new subunit influenza vaccine: acceptability compared with standard vaccines and effect of dose on antigenicity. J Infect Dis (1972) 2.06
Ototoxicity of gentamicin in man: a survey and controlled analysis of clinical experience in the United States. J Infect Dis (1971) 1.97
Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin. J Infect Dis (1971) 1.89
An evaluation of the use of statistical methodology in the Journal of Infectious Diseases. J Infect Dis (1984) 1.82
Alterations in outer membrane proteins of Pseudomonas aeruginosa associated with selective resistance to quinolones. Antimicrob Agents Chemother (1988) 1.70
Viremia in Asian influenza. Trans Assoc Am Physicians (1966) 1.70
Humoral and cellular response in humans after immunization with influenza vaccine. Infect Immun (1973) 1.54
Antibacterial activity of cinoxacin in vitro. Antimicrob Agents Chemother (1975) 1.50
Effect of isoprinosine against influenza and some other viruses causing respiratory diseases. Antimicrob Agents Chemother (1972) 1.48
Comparative in vitro activity of azlocillin, ampicillin, mezlocillin, piperacillin, and ticarcillin, alone and in combination with an aminoglycoside. Antimicrob Agents Chemother (1979) 1.47
Acute respiratory illness among immunized and nonimmunized patients with high-risk factors during a split season of influenza A and B. J Infect Dis (1988) 1.46
Neutralizing activity in nasal secretions and serum in resistance of volunteers to parainfluenza virus type 2. J Immunol (1968) 1.42
Observations of the staphylococcal nasal carrier state. Ann N Y Acad Sci (1965) 1.34
Production of interferon in volunteers infected with Asian influenza. J Infect Dis (1970) 1.33
Increased virus shedding with aspirin treatment of rhinovirus infection. JAMA (1975) 1.31
Netilmicin: clinical efficacy, tolerance, and toxicity. Antimicrob Agents Chemother (1978) 1.29
Prevention of illness from rhinovirus infection by a topical interferon inducer. N Engl J Med (1974) 1.27
High-pressure liquid chromatographic assay of netilmicin in plasma. Antimicrob Agents Chemother (1977) 1.21
Viruses causing common respiratory infection in man. IV. Reoviruses and Adenoviruses. J Infect Dis (1973) 1.17
Use and withdrawal of amantadine chemoprophylaxis during epidemic influenza A. Am Rev Respir Dis (1976) 1.15
Viremia with herpes simplex type 1 in adults. Four nonfatal cases, one with features of chicken pox. Ann Intern Med (1976) 1.15
Prospective study of prevalence, incidence, and source of herpesvirus infections in patients with renal allografts. J Infect Dis (1977) 1.14
Antiviral agents in influenza--summary of Influenza Workshop VIII. J Infect Dis (1976) 1.12
Attitudes and behavior of health care personnel regarding the use and efficacy of influenza vaccine. J Infect Dis (1985) 1.10
Viruses causing common respiratory infections in man. J Infect Dis (1973) 1.08
The limited effect of nasal interferon induced by rhinovirus and a topical chemical inducer on the course of infection. J Infect Dis (1973) 1.05
The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis (1990) 1.05
Acute-phase decrease of T lymphocyte subsets in rhinovirus infection. J Infect Dis (1986) 1.04
Prevention and control of influenza by chemoprophylaxis and chemotherapy. Prospects from examination of recent experience. JAMA (1976) 1.02
Methods for the clinical evaluation of antibiotics in urinary tract infections. Scand J Infect Dis Suppl (1978) 1.02
Efficacy of cinoxacin in urinary tract infections. Antimicrob Agents Chemother (1976) 1.01
Herpes virus latency in spinal ganglia of mice without illness. Proc Soc Exp Biol Med (1974) 1.00
Protection with split and whole virus vaccines against influenza. Arch Intern Med (1973) 0.99
Biphasic, concentration-dependent and rate-limited, concentration-independent bacterial killing by an aminoglycoside antibiotic. J Infect Dis (1984) 0.98
Topical enviroxime against rhinovirus infection. Antimicrob Agents Chemother (1982) 0.97
Fungal and mycobacterial infections in patients infected with the human immunodeficiency virus. J Antimicrob Chemother (1989) 0.97
Study of delayed hypersensitivity to myxoviruses induced by vaccines. Appl Microbiol (1969) 0.94
Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. JAMA (1985) 0.91
Nasal-secretion leukocyte populations determined by flow cytometry during acute rhinovirus infection. J Med Virol (1988) 0.91
Infectious Diseases Society of America. Trials of interferon therapy for multiple sclerosis. J Infect Dis (1982) 0.91
Sequence analysis of an HIV-1 isolate which displays unusually high-level AZT resistance in vitro. J Med Virol (1992) 0.90
From the Infectious Diseases Society of America. Hospital epidemiology and infection control: the changing role of the specialist in infectious diseases. J Infect Dis (1981) 0.89
Gentamicin plus carbenicillin. Lancet (1971) 0.89
Search for latent cytomegalovirus in renal allografts. Infect Immun (1978) 0.89
Viruses causing common respiratory infections in man. V. influenza A (Asian). J Infect Dis (1975) 0.89
Experimental pseudomonas osteomyelitis: treatment with sisomicin and carbenicillin. J Bone Joint Surg Am (1974) 0.87
Long-term oral ciprofloxacin: experience in the treatment of incurable infective endocarditis. Am J Med (1988) 0.87
Intravenous and intraocular ganciclovir for CMV retinitis in patients with AIDS or chemotherapeutic immunosuppression. Br J Ophthalmol (1988) 0.87
Viruses causing common respiratory infections in man. 3. Respiratory syncytial viruses and coronaviruses. J Infect Dis (1973) 0.87
Sensitivity of influenza A virus to amantadine. J Infect Dis (1977) 0.84
In vitro and clinical effects of cephaloridine: a semisynthetic antibiotic. Am J Med Sci (1967) 0.83
Live and killed adenovirus vaccines for the prevention of acute respiratory disease in recruits. Antimicrob Agents Chemother (Bethesda) (1965) 0.83
Perspective from a quarter century of antibiotic usage. JAMA (1974) 0.83
Clinical manifestations of infections with herpesviruses after kidney transplantation: a prospective study of various syndromes. Ann Surg (1978) 0.83
Assay of aminoglycoside antibiotics in clinical specimens. J Infect Dis (1975) 0.83
Isolation of Mycoplasma pneumoniae from adults with respiratory infections. Arch Intern Med (1966) 0.82
Stress and sugar control in children with insulin-dependent diabetes mellitus. J Pediatr (1981) 0.82
Communicability of enteric live adenovirus type 4 vaccine in families. J Infect Dis (1969) 0.81
Spread of enteric live adenovirus type 4 vaccine in married couples. J Infect Dis (1969) 0.81
Effect of a topical interferon inducer on rhinovirus infections in volunteers. J Infect Dis (1976) 0.81
Dual respiratory infection with parainfluenza and rhinovirus. The pathogenesis of transmitted infection in volunteers. Am Rev Respir Dis (1966) 0.81
Comparison of ciprofloxacin and beta-lactam antibiotics in the treatment of urinary tract infections and alteration of fecal flora. Am J Med (1987) 0.80
Comparative activity of bacterial beta-lactamases on penicillins and cephalosporins. J Infect Dis (1973) 0.80
Oral ribavirin treatment of influenza A and B. Antimicrob Agents Chemother (1987) 0.80
Actinobacillus actinomycetemcomitans endocarditis in a patient with a prosthetic aortic valve. Infection (1977) 0.80
Oxolinic acid treatment of urinary-tract infections. Antimicrob Agents Chemother (Bethesda) (1967) 0.79
Increasing experience for the evaluation of antiviral chemotherapy. J Infect Dis (1980) 0.79
Characteristics of vaccine-induced and natural infection with adenovirus type 4 in naval recruits. Am J Epidemiol (1968) 0.78
Live and inactivated adenovirus vaccines for the prevention of acute respiratory illness in naval recruits. Am J Epidemiol (1968) 0.77
Mass enteric live adenovirus vaccination during epidemic ARD. JAMA (1968) 0.77
Influence of adrenocorticotropin and adrenalectomy on gonadotropin secretion in immature rats. Neuroendocrinology (1982) 0.76
The key role of aminoglycosides in antibacterial therapy and prophylaxis. J Antimicrob Chemother (1984) 0.76
A perspective from controlled investigations of chemotherapy for viral respiratory infections. J Infect Dis (1976) 0.76
Clinical assessment of newer antibiotics. Effect in compromised hosts and drug combinations. Scand J Infect Dis Suppl (1980) 0.76
Antiviral chemotherapy--a frontier for health and learning. Yale J Biol Med (1983) 0.75
ECHO-11 as a respiratory virus: quantitation of infection in man. J Clin Invest (1968) 0.75
Double-blind comparison of cephacetrile with cephalothin-cephaloridine. Antimicrob Agents Chemother (1974) 0.75
Is behavior therapy a threat to black clients? J Natl Med Assoc (1976) 0.75
A new subunit influenza vaccine; acceptability compared with standard vaccines and antigenicity in increasing dosage. Postgrad Med J (1973) 0.75
Self-administered histories let doctor concentrate on patient. Mod Hosp (1971) 0.75
Introduction of gentamicin. Laboratory and clinical trials. G Ital Chemioter (1971) 0.75
Experience with vaccines--summary. Natl Cancer Inst Monogr (1968) 0.75
Therapy with combinations of penicillin analogues in urinary-tract infections. Antimicrob Agents Chemother (Bethesda) (1969) 0.75
Diagnosis and importance of asymptomatic bacteriuria in adults. Infection (1975) 0.75
The new DRGs -- ICD-9-CM. J Am Med Rec Assoc (1982) 0.75
Infectious Diseases Society of America. Concepts in training, performance in practice. J Infect Dis (1975) 0.75
Effects of water and furosemide-induced diuresis on the acquisition and course of experimental pyelonephritis. J Lab Clin Med (1971) 0.75
The evaluation of antiviral drugs in volunteers. Prog Med Virol (1968) 0.75
The pathogenesis and treatment of pyelonephritis. Int Z Klin Pharmakol Ther Toxikol (1968) 0.75
Viruses causing common respiratory infections in man. II. Enteroviruses and paramyxoviruses. J Infect Dis (1973) 0.75